Have a feature idea you'd love to see implemented?
Let us know!
VOR Vor Biopharma Inc
Price (delayed)
$0.7961
Market cap
$54.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.64
Enterprise value
$32.31M
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that
Highlights
VOR's EPS is up by 13% YoY and by 5% from the previous quarter
The debt is down by 10% YoY and by 2.9% from the previous quarter
Vor Biopharma's equity has plunged by 58% YoY and by 26% from the previous quarter
Vor Biopharma's quick ratio has plunged by 57% YoY and by 29% from the previous quarter
Key stats
What are the main financial stats of VOR
Market
Valuations
Earnings
Shares outstanding
68.67M
Market cap
$54.67M
Enterprise value
$32.31M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$112.46M
EBITDA
-$103.94M
Free cash flow
-$99.89M
Per share
Balance sheet
Liquidity
EPS
-$1.64
Free cash flow per share
-$1.46
Book value per share
$1.07
Revenue per share
$0
TBVPS
$1.69
Total assets
$115.99M
Total liabilities
$43.04M
Debt
$32.85M
Equity
$72.96M
Working capital
$52.95M
Debt to equity
0.45
Current ratio
4.69
Quick ratio
4.55
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-72.2%
Return on equity
-101.1%
Return on invested capital
-92.2%
Return on capital employed
-110.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VOR stock price
How has the Vor Biopharma stock price performed over time
Intraday
0.16%
1 week
-11.28%
1 month
17.38%
1 year
-54.77%
YTD
-64.62%
QTD
13.73%
Financial performance
How have Vor Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$118M
Net income
-$112.46M
Gross margin
N/A
Net margin
N/A
The net income has grown by 4.8% from the previous quarter and by 2.6% YoY
The company's operating income rose by 5% QoQ and by 3.8% YoY
Growth
What is Vor Biopharma's growth rate over time
Valuation
What is Vor Biopharma stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VOR's EPS is up by 13% YoY and by 5% from the previous quarter
Vor Biopharma's equity has plunged by 58% YoY and by 26% from the previous quarter
VOR's price to book (P/B) is 17% less than its last 4 quarters average of 0.9
Efficiency
How efficient is Vor Biopharma business performance
The return on invested capital has dropped by 92% year-on-year and by 18% since the previous quarter
The company's return on equity has shrunk by 88% YoY and by 17% QoQ
The return on assets has dropped by 64% year-on-year and by 12% since the previous quarter
Dividends
What is VOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VOR.
Financial health
How did Vor Biopharma financials performed over time
Vor Biopharma's total assets is 170% more than its total liabilities
Vor Biopharma's quick ratio has plunged by 57% YoY and by 29% from the previous quarter
Vor Biopharma's current ratio has plunged by 56% YoY and by 28% from the previous quarter
The debt is 55% less than the equity
Vor Biopharma's debt to equity has surged by 114% YoY and by 32% QoQ
Vor Biopharma's equity has plunged by 58% YoY and by 26% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.